This site is intended for healthcare professionals
News

FDA provide complete response letter for Ayvakit in fourth-line gastrointestinal stromal tumor.- Blueprint Medicines

Read time: 1 mins
Last updated:18th May 2020
Published:16th May 2020
Condition: GIST
Type: drug
Register for free exclusive healthcare eLearning resources


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest